Personalized Intensification of Treatment for Hormone-Sensitive Prostate Cancer

Scientists discuss the personalized management of both non-metastatic and metastatic hormone-sensitive prostate cancer, including how to select patients for docetaxel, choice of androgen receptor pathway inhibitors and use of radiotherapy to primary and metastatic disease sites.